How Biotechs Die: Bankruptcy Risk on the Balance Sheet

The problem: most biotech positions don’t die in a single CRL. They die slowly, a quarter at a time, as the cash runs out. These have gone to zero: an FDA-approved antibiotic that couldn’t sell, a cancer vaccine company that filed for Chapter 11 with $61.7 million still in the bank. Here’s how to see it coming before the stock does.

The solution: run the runway math, then watch for four tripwires in order of severity: going-concern language, the reverse split, dilutive offerings at ever-lower prices, and the Chapter 11 filing itself.

Step 1: Run the runway math

A pre-revenue biotech has one resource that matters: cash. The runway formula is simple.

Cash and cash equivalents plus short-term investments, divided by quarterly operating burn, equals quarters of runway. Multiply by three for months.

You find both numbers in the 10-Q. Cash and short-term investments sit on the balance sheet. The burn rate sits on the cash flow statement under operating activities. Use the cash flow statement number, never the press release number, which assumes zero new hiring and zero trial acceleration.

The thresholds: under 12 months of runway is a red flag. Under six months is a countdown. The full mechanics of how that runway evaporates are in the biotech dilution survival guide.

Step 2: Watch the tripwires, in order

These four usually fire in sequence, and each one is cheaper to spot than the last.

Tripwire 1: the going-concern note. When the auditor writes that there’s “substantial doubt” about the company’s ability to continue as a going concern, the runway math no longer matters. This language appears when cash covers less than about a year, and it’s usually the last written warning before a raise or a fire sale. Find it in the 10-K and the auditor opinion. More on reading the footnotes in the accounting red flags guide.

Tripwire 2: the Nasdaq minimum bid notice and the reverse split. Nasdaq delists a stock that trades below $1 for 30 consecutive business days. The company’s fix is a reverse split, which mechanically raises the share price and changes nothing about the value. Gossamer Bio is the template: a $0.20 stock with a $66 million market cap that missed its Phase 3 primary endpoint and now faces a near-certain reverse split to stay listed. The reverse split is a tell that appears dozens of times, and it always means the same thing: the company is managing the listing, not the business. See the full Gossamer write-up.

Tripwire 3: dilutive offerings at ever-lower prices. Once the stock is below a dollar, every capital raise is catastrophically dilutive because the company has to issue enormous numbers of shares. The raise that comes after the reverse split prices even lower. This is the dilution death spiral.

Tripwire 4: the Chapter 11 filing and the asset auction. The terminal event. The company files, the equity is wiped or nearly wiped, and the assets go to auction for cents on the dollar.

Step 3: Learn the Achaogen lesson

Achaogen is the case study that should be burned into every biotech investor’s memory. The company won FDA approval for plazomicin in June 2018, a novel antibiotic for drug-resistant infections. It reported $800,000 in total sales for all of 2018. Nine months after approval, it filed for bankruptcy. The assets sold at auction for $16 million.

Approval is not survival. A drug can clear the FDA and still fail commercially, and when the sales don’t come, the cash that funded the approval is already gone. The full Achaogen story is in the AMR crisis analysis.

Step 4: Learn the Gritstone lesson

Gritstone is the same disease in a different organ. The company’s individualized cancer vaccine program missed, the stock dropped, and Gritstone filed for Chapter 11 with $61.7 million in cash still on the balance sheet. That’s the part people miss: a company can file for bankruptcy with cash in the bank, because the question isn’t whether it has money today, it’s whether it can fund the next 12 months of a program that no longer has a clear path.

The data readout and the balance sheet are the same trade. When the data misses, the balance sheet is what decides whether you get a recovery or a zero. The Gritstone story sits inside the cancer vaccines analysis.

Step 5: Know what shareholders actually get

In a Chapter 11, the order is fixed: secured creditors first, then unsecured creditors, then equity holders last. Equity is usually wiped to zero. The assets get sold, and whatever’s left goes to creditors, not shareholders.

This is why “buying the dip” on a sub-$1 biotech near a reverse split is usually catching a falling knife, not finding a turnaround. The company is telling you, in four separate filings, that it’s running out of time. When you buy that dip, you’re not buying the business. You’re buying the last remaining hope that a buyer or a miracle shows up before the creditors get paid.

Step 6: The contrarian case, and its limits

There is one corner where distressed biotech can work, and it’s narrow. When cash per share exceeds the stock price, the equity has a hard floor. If a genuine catalyst is on the calendar, a data readout, an approval, a partner milestone, that equity becomes a lottery ticket with a defined downside.

The math: if the company holds $1.10 per share in cash and trades at $0.90, your downside to a wind-down is about $0.20, and your upside to a positive readout is a multiple. That’s a real, if brutal, option.

But size it like a lottery ticket, not an investment. This is a sub-2% position, and only when the cash floor is real and the catalyst is dated. Most “cheap” biotechs are not this. Most are Gritstone and Gossamer: cash that’s spoken for, a catalyst that already failed, and a reverse split on the way.

Common mistakes

Buying the dip below a dollar. You’re betting against the reverse split, the dilution, and the creditors, all at once.

Ignoring the going-concern note. It’s the single most reliable predictor of the next raise or the next filing, and most investors never read it.

Confusing a reverse split with value. The price goes up, the value doesn’t. You own fewer shares of the same struggling company.

Treating cash as yours. Cash belongs to creditors in a bankruptcy. Cash per share only matters if the company is a going concern, which is exactly what’s in doubt.

Final checklist: five numbers to score insolvency risk in five minutes

Pull any biotech’s 10-Q and answer these:

1. Quarters of runway: cash plus short-term investments, divided by quarterly operating burn.
2. Going-concern note: does the 10-K or auditor opinion contain “substantial doubt” language?
3. Cash per share versus the stock price.
4. Share count trend: is it climbing quarter over quarter from dilution?
5. Nasdaq bid price versus the $1.00 threshold.

If the runway is under six months, the going-concern note is live, and the stock is below a dollar, you’re not looking at an investment. You’re looking at a bankruptcy in progress. All five numbers come straight from the filings on SEC EDGAR.